Cullinan Associates’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$5.99M Sell
46,620
-1,425
-3% -$167K 0.45% 55
2026
Q1
$5.78M Sell
48,045
-2,489
-5% -$287K 0.47% 55
2025
Q4
$5.32M Buy
50,534
+910
+2% +$85.4K 0.36% 60
2025
Q3
$4.16M Buy
49,624
+30
+0.1% +$2.47K 0.27% 69
2025
Q2
$3.93M Buy
49,594
+4,275
+9% +$340K 0.26% 72
2025
Q1
$4.07M Buy
45,319
+441
+1% +$41.2K 0.29% 76
2024
Q4
$4.46M Sell
44,878
-1,390
-3% -$143K 0.29% 69
2024
Q3
$4.94M Buy
46,268
+2,300
+5% +$273K 0.28% 75
2024
Q2
$5.44M Buy
43,968
+3,720
+9% +$479K 0.31% 66
2024
Q1
$5.31M Sell
40,248
-18,731
-32% -$2.31M 0.3% 70
2023
Q4
$6.43M Sell
58,979
-6,284
-10% -$652K 0.36% 64
2023
Q3
$6.72M Sell
65,263
-6,481
-9% -$699K 0.39% 61
2023
Q2
$8.28M Sell
71,744
-5,102
-7% -$579K 0.46% 60
2023
Q1
$8.18M Buy
76,846
+20,104
+35% +$2.17M 0.48% 58
2022
Q4
$6.3M Buy
56,742
+2,923
+5% +$299K 0.35% 67
2022
Q3
$4.63M Buy
53,819
+7,276
+16% +$650K 0.29% 82
2022
Q2
$4.24M Sell
46,543
-5,440
-10% -$482K 0.26% 86
2022
Q1
$4.26M Buy
51,983
+9,460
+22% +$746K 0.22% 98
2021
Q4
$3.26M Sell
42,523
-68,210
-62% -$5.43M 0.17% 111
2021
Q3
$8.32M Sell
110,733
-1,046
-0.9% -$79.6K 0.46% 61
2021
Q2
$8.69M Sell
111,779
-22,133
-17% -$1.65M 0.49% 63
2021
Q1
$9.85M Sell
133,912
-404
-0.3% -$29.8K 0.57% 52
2020
Q4
$10.5M Buy
134,316
+3,860
+3% +$295K 0.63% 41
2020
Q3
$10.3M Buy
130,456
+28,899
+28% +$2.26M 0.67% 32
2020
Q2
$7.49M Sell
101,557
-11,864
-10% -$893K 0.53% 44
2020
Q1
$8.33M Sell
113,421
-3,656
-3% -$287K 0.68% 35
2019
Q4
$10.2M Sell
117,077
-1,301
-1% -$107K 0.68% 37
2019
Q3
$9.51M Sell
118,378
-209
-0.2% -$16.8K 0.68% 42
2019
Q2
$9.49M Sell
118,587
-7,389
-6% -$566K 0.69% 38
2019
Q1
$10M Buy
125,976
+1,520
+1% +$114K 0.75% 31
2018
Q4
$9.07M Sell
124,456
-4,140
-3% -$292K 0.75% 29
2018
Q3
$8.71M Sell
128,596
-36,680
-22% -$2.34M 0.63% 42
2018
Q2
$9.57M Sell
165,276
-7,126
-4% -$402K 0.73% 31
2018
Q1
$8.96M Sell
172,402
-582
-0.3% -$31.4K 0.68% 35
2017
Q4
$9.29M Sell
172,984
-68,330
-28% -$3.79M 0.68% 36
2017
Q3
$14.7M Sell
241,314
-314
-0.1% -$19K 1.14% 14
2017
Q2
$14.8M Buy
241,628
+7,381
+3% +$449K 1.15% 14
2017
Q1
$14.2M Buy
234,247
+584
+0.2% +$35.4K 1.16% 14
2016
Q4
$13.1M Buy
233,663
+3,039
+1% +$178K 1.12% 15
2016
Q3
$13.7M Sell
230,624
-11,633
-5% -$680K 1.17% 13
2016
Q2
$13.3M Buy
242,257
+4,245
+2% +$226K 1.08% 16
2016
Q1
$12M Sell
238,012
-4,609
-2% -$226K 1.03% 16
2015
Q4
$12.2M Sell
242,621
-3,019
-1% -$152K 1.06% 18
2015
Q3
$11.6M Buy
245,640
+89,389
+57% +$4.75M 1.06% 15
2015
Q2
$8.49M Buy
156,251
+4,350
+3% +$244K 0.7% 30
2015
Q1
$8.33M Sell
151,901
-48,548
-24% -$2.75M 0.65% 35
2014
Q4
$10.9M Buy
200,449
+12,194
+6% +$679K 1.15% 13
2014
Q3
$10.6M Buy
188,255
+34,411
+22% +$1.93M 1.21% 12
2014
Q2
$6.82M Sell
153,844
-38,960
-20% -$2.13M 1.11% 8
2014
Q1
$10.4M Sell
192,804
-12,523
-6% -$648K 1.19% 12
2013
Q4
$9.81M Buy
205,327
+17,161
+9% +$784K 1.14% 11
2013
Q3
$8.55M Sell
188,166
-1,048
-0.6% -$47.8K 1.15% 11
2013
Q2
$8.39M Buy
+189,214
New +$8.45M 1.13% 10

Other funds holding MRK

Cullinan Associates's MRK Position: Q2 2026 in Review

Cullinan Associates reduced its Merck (MRK) stake by 3% in Q2 2026, selling an estimated $167K and leaving 46,620 shares worth $5.99M. The position accounts for 0.45% of the portfolio, ranked #55.

Cullinan Associates first reported a position in MRK in Q2 2013 and has held it in 53 quarters since. The position peaked at $14.8M in Q2 2017. 1,660 funds tracked by Wall St. Rank hold MRK as of Q2 2026.

  • Cullinan Associates held 46,620 shares of Merck worth $5.99M as of Q2 2026.
  • Cullinan Associates sold 1,425 Merck shares in Q2 2026, an estimated $167K.
  • Merck made up 0.45% of Cullinan Associates's portfolio in Q2 2026, its #55 holding.
  • Cullinan Associates first reported a position in Merck in Q2 2013 and has held it in 53 quarters since.
  • Cullinan Associates's Merck position peaked at $14.8M in Q2 2017.
  • 1,660 funds tracked by Wall St. Rank held Merck as of Q2 2026.

Based on Cullinan Associates's 13F filing for Q2 2026, filed 29 Jul 2026.